Metabolic effects of brown fat in transitioning from hyperthyroidism to euthyroidism.
Adipose Tissue, Brown
/ diagnostic imaging
Adult
Aged
Antithyroid Agents
/ pharmacology
Body Composition
/ drug effects
Carbimazole
/ therapeutic use
Energy Metabolism
/ drug effects
Female
Fluorodeoxyglucose F18
Graves Disease
/ drug therapy
Humans
Hyperthyroidism
/ diagnosis
Magnetic Resonance Imaging
Male
Methimazole
/ therapeutic use
Middle Aged
Positron-Emission Tomography
Remission Induction
Singapore
Thermogenesis
/ drug effects
Thyroid Gland
/ diagnostic imaging
Young Adult
Journal
European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848
Informations de publication
Date de publication:
27 Aug 2021
27 Aug 2021
Historique:
received:
08
04
2021
accepted:
03
08
2021
pubmed:
4
8
2021
medline:
9
9
2021
entrez:
3
8
2021
Statut:
epublish
Résumé
Brown adipose tissue (BAT) controls metabolic rate through thermogenesis. As its regulatory factors during the transition from hyperthyroidism to euthyroidism are not well established, our study investigated the relationships between supraclavicular brown adipose tissue (sBAT) activity and physiological/metabolic changes with changes in thyroid status. Participants with newly diagnosed Graves' disease were recruited. A thionamide antithyroid drug (ATD) such as carbimazole (CMZ) or thiamazole (TMZ) was prescribed in every case. All underwent energy expenditure (EE) measurement and supraclavicular infrared thermography (IRT) within a chamber calorimeter, as well as 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography/magnetic resonance (PET/MR) imaging scanning, with clinical and biochemical parameters measured during hyperthyroidism and repeated in early euthyroidism. PET sBAT mean/maximum standardized uptake value (SUV mean/max), MR supraclavicular fat fraction (sFF) and mean temperature (Tscv) quantified sBAT activity. Twenty-one (16 female/5 male) participants aged 39.5 ± 2.5 years completed the study. The average duration to attain euthyroidism was 28.6 ± 2.3 weeks. Eight participants were BAT-positive while 13 were BAT-negative. sFF increased with euthyroidism (72.3 ± 1.4% to 76.8 ± 1.4%; P < 0.01), but no changes were observed in PET SUV mean and Tscv. Significant changes in serum-free triiodothyronine (FT3) levels were related to BAT status (interaction P value = 0.04). FT3 concentration at hyperthyroid state was positively associated with sBAT PET SUV mean (r = 0.58, P = 0.01) and resting metabolic rate (RMR) (P < 0.01). Hyperthyroidism does not consistently lead to a detectable increase in BAT activity. FT3 reduction during the transition to euthyroidism correlated with BAT activity.
Identifiants
pubmed: 34342595
doi: 10.1530/EJE-21-0366
pii: EJE-21-0366
pmc: PMC8428075
doi:
pii:
Substances chimiques
Antithyroid Agents
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Methimazole
554Z48XN5E
Carbimazole
8KQ660G60G
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
553-563Références
Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):8649-8654
pubmed: 28739898
J Clin Invest. 2001 Nov;108(9):1379-85
pubmed: 11696583
Diabetes. 2015 Jul;64(7):2388-97
pubmed: 25677914
Magn Reson Med. 2010 Jan;63(1):79-90
pubmed: 19859956
Horm Metab Res. 2013 Oct;45(11):774-85
pubmed: 23803970
J Clin Endocrinol Metab. 1998 Dec;83(12):4269-73
pubmed: 9851762
Sci Rep. 2016 Dec 12;6:38124
pubmed: 27941950
Mol Cell Endocrinol. 1990 Oct 1;73(1):27-34
pubmed: 2292337
N Engl J Med. 2009 Apr 9;360(15):1509-17
pubmed: 19357406
Diabetes. 2010 Jul;59(7):1789-93
pubmed: 20357363
Eur J Clin Nutr. 2016 Dec;70(12):1414-1419
pubmed: 27460267
Clin Obes. 2019 Oct;9(5):e12328
pubmed: 31267667
Endocrine. 2018 Nov;62(2):496-500
pubmed: 30066287
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31912874
Front Endocrinol (Lausanne). 2020 Aug 07;11:421
pubmed: 32849257
Thyroid. 2017 Jan;27(1):1-10
pubmed: 27750020
Endocrinology. 2020 Jul 1;161(7):
pubmed: 32242612
Autophagy. 2019 Jan;15(1):131-150
pubmed: 30209975
Endocrinology. 2010 Jan;151(1):432-40
pubmed: 19906816
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):10001-5
pubmed: 22665804
Mol Endocrinol. 2004 Feb;18(2):384-401
pubmed: 14630998
Magn Reson Med. 2020 May;83(5):1565-1576
pubmed: 31782551
Endocr Pract. 2008 Nov;14(8):973-8
pubmed: 19095595
Int J Obes (Lond). 2014 Jun;38(6):812-7
pubmed: 24213309
PLoS One. 2016 Jan 19;11(1):e0145049
pubmed: 26784028
J Clin Invest. 1985 Dec;76(6):2296-305
pubmed: 4077981
Nature. 1962 Mar 17;193:1058-60
pubmed: 13919771
Thyroid. 1995 Dec;5(6):481-92
pubmed: 8808101
Am J Clin Nutr. 2018 Jan 1;107(1):62-70
pubmed: 29381803
N Engl J Med. 2009 Apr 9;360(15):1500-8
pubmed: 19357405
Am J Clin Nutr. 2012 Apr;95(4):845-50
pubmed: 22378725
Nat Med. 2011 Feb;17(2):200-5
pubmed: 21258337
Am J Physiol Cell Physiol. 2012 Jan 15;302(2):C463-72
pubmed: 22075692
Cell Metab. 2016 Aug 9;24(2):210-22
pubmed: 27508870
Curr Opin Lipidol. 2012 Jun;23(3):190-5
pubmed: 22449813
J Magn Reson Imaging. 2015 Apr;41(4):924-34
pubmed: 24803305
Magn Reson Med. 2012 Aug;68(2):378-88
pubmed: 22693111
J Clin Endocrinol Metab. 2010 Jan;95(1):256-62
pubmed: 19897683
Nat Commun. 2017 Jan 30;8:14146
pubmed: 28134339
Sci Rep. 2020 Jun 15;10(1):9661
pubmed: 32541662
Clin Endocrinol Metab. 1984 Nov;13(3):581-95
pubmed: 6391756
Nat Med. 2010 Sep;16(9):1001-8
pubmed: 20802499
Physiol Rev. 2006 Apr;86(2):435-64
pubmed: 16601266
Indian J Med Res. 2012 Aug;136(2):242-8
pubmed: 22960891
J Clin Invest. 2006 Oct;116(10):2571-9
pubmed: 17016550
Obes Facts. 2020;13(3):331-343
pubmed: 32564012
Thyroid. 2016 Oct;26(10):1422-1430
pubmed: 27465032
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Physiol Rev. 2014 Apr;94(2):355-82
pubmed: 24692351
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1200-1207
pubmed: 28323929
Magn Reson Med. 2017 Nov;78(5):1922-1932
pubmed: 28112821
Biosci Rep. 2005 Jun-Aug;25(3-4):191-208
pubmed: 16283553
Diabetes Metab Res Rev. 2014 Sep;30(6):513-20
pubmed: 24823620
Obesity (Silver Spring). 2019 Sep;27(9):1434-1442
pubmed: 31301122
J Clin Endocrinol Metab. 2014 Jan;99(1):E28-35
pubmed: 24152690
N Engl J Med. 2009 Apr 9;360(15):1518-25
pubmed: 19357407